Stay updated with breaking news from Precision Pairing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levelsNo neurotoxicity or dose-limiting toxicities observedTwo out of nine patients showed early... | June 18, 2023
Martinsried/Munich, April 18, 2023, Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents preclinical... | April 18, 2023
Martinsried/Munich, April 04, 2023. Medigene AG is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dr.... | April 4, 2023
Press Release: Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene's proprietary T cell receptors in novel cell constructs
Martinsried/Munich, April 3, 2023. Medigene AG , an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, and the National... | April 3, 2023